Boston Scientific (BSX) closed the most recent trading day at $95.12, moving -0.14% from the previous trading session. The stock's change was less than the S&P 500's daily gain of 0.13%. Meanwhile, the Dow experienced a drop of 1.33%, and the technology-dominated Nasdaq saw a decrease of 0.13%.

The medical device manufacturer's shares have seen a decrease of 5.44% over the last month, surpassing the Medical sector's loss of 8.46% and the S&P 500's loss of 6.3%.

The investment community will be paying close attention to the earnings performance of Boston Scientific in its upcoming release. The company is slated to reveal its earnings on April 23, 2025. The company is forecasted to report an EPS of $0.67, showcasing a 19.64% upward movement from the corresponding quarter of the prior year. Simultaneously, our latest consensus estimate expects the revenue to be $4.56 billion, showing a 18.2% escalation compared to the year-ago quarter.

Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $2.85 per share and revenue of $19.13 billion, indicating changes of +13.55% and +14.21%, respectively, compared to the previous year.

Furthermore, it would be beneficial for investors to monitor any recent shifts in analyst projections for Boston Scientific. These revisions help to show the ever-changing nature of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits.

Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.

The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Boston Scientific presently features a Zacks Rank of #3 (Hold).

In the context of valuation, Boston Scientific is at present trading with a Forward P/E ratio of 33.44. This represents a premium compared to its industry's average Forward P/E of 14.92.

We can also see that BSX currently has a PEG ratio of 2.52. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The average PEG ratio for the Medical - Products industry stood at 2.03 at the close of the market yesterday.

The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 184, putting it in the bottom 26% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Boston Scientific Corporation (BSX) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research